Blank Bio

Founded in 2025 and headquartered in San Francisco, US, Blank Bio focuses on RNA intelligence solutions.Blank Bio’s core offerings center around advanced RNA intelligence solutions designed to optimize clinical trial outcomes in precision oncology. The company specializes in two primary applications: disease trajectory modeling and patient selection. Through sophisticated RNA prognostic scores, Blank Bio predicts disease progression based on individual molecular profiles, enabling pharmaceutical teams to design more efficient trials that achieve statistical power with fewer patients. Additionally, the patient selection service helps identify biological differences among patients to pinpoint those most likely to respond to specific therapies, thereby enhancing treatment efficacy and informing combination strategies.Blank Bio's revenue model is structured around partnerships and B2B transactions with pharmaceutical companies, focusing on delivering tailored insights through its RNA intelligence services. The company establishes collaborations with clients, which involve subscriptions or contracts that allow access to its modeling capabilities and analytical tools. Client engagements typically revolve around the integration of Blank Bio's predictive models into the clients' clinical trial processes, thus facilitating improved patient selection and designing trials that maximize efficiency. Specific pricing plans are structured based on the scope of services provided, aligning with the client's needs and the complexity of the required analyses. The company plans to launch new RNA models aimed at enhancing clinical trial efficacy within the next 18 months. Additionally, Blank Bio is targeting expansion into European markets to meet increasing demand for precision oncology solutions, with initiatives aimed for completion by the end of 2027.

1. Seed

   May 19, 2026

   Amount

   $7.2M

   Investors

   Locked